What is ADRx?
ADRx is at the forefront of transforming atomic structures into novel small molecule therapies. The company pioneers the application of structure-based design to disrupt protein aggregation diseases, a critical approach for developing therapeutics for neurodegenerative disorders. By targeting patient-derived pathological protein structures, ADRx has successfully identified and is developing innovative treatments. Their methodology enables the discovery of small molecule modulators that effectively address pathological protein-protein interactions, including those involving amyloids and biomolecular condensates. This sophisticated approach positions ADRx as a key player for researchers and healthcare providers seeking advanced solutions in neurodegenerative disease treatment.
How much funding has ADRx raised?
ADRx has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for ADRx?
With the recent influx of capital, ADRx is poised for accelerated growth and the advancement of its therapeutic pipeline. The company's focus on late-stage development and strategic investments suggests a trajectory towards clinical trials and potential market entry for its novel small molecule therapies. This significant backing will likely fuel further research and development, enabling ADRx to expand its capabilities in drug discovery and solidify its position in the competitive landscape of neurodegenerative disease treatment. The company's commitment to disrupting protein aggregation diseases through innovative structural design indicates a strong potential for future breakthroughs.
See full ADRx company page
